Precision oncology for RET-related tumors
A Verrienti, G Grani, M Sponziello, V Pecce… - Frontiers in …, 2022 - frontiersin.org
Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET
gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) …
gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) …
Design of new drugs for medullary thyroid carcinoma
Y Li, Z Luo, X Wang, S Zhang, H Hei, J Qin - Frontiers in Oncology, 2022 - frontiersin.org
Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors,
which seriously affects human health. Although surgical resection offers a potentially …
which seriously affects human health. Although surgical resection offers a potentially …
A case report of poor response to selpercatinib in the presence of a 632_633 RET deletion
Background: Genomic deletions in medullary thyroid cancer (MTC) are rare. Selpercatinib is
a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. We report a 35 …
a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. We report a 35 …